Argos Therapeutics Appoints Dr. Ralph Snyderman and Irackly

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Argos Therapeutics Appoints Dr. Ralph Snyderman and Irackly Mtibelishvily to the Company’s Board of Directors

DURHAM, N.C., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq: ARGS ) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced the appointment of Ralph Snyderman, M.D., and Irackly Mtibelishvily, LL.M., to the company's board of directors.

“It is a privilege to welcome a pair of profoundly accomplished professionals to the Argos board of directors who offer renowned expertise in each of their respective fields,” said Jeff Abbey, president and CEO of Argos. “Dr. Snyderman is widely referred to as the ‘father of personalized medicine’ and his experience running the Duke University Health System as well as his senior leadership roles at Genentech will help guide us as we advance our individualized immunotherapy through the final stages of clinical development, assess indication expansion and approach our goal of becoming a fully-integrated commercial company. In addition, Irackly Mtibelishvily is globally recognized as one of the most experienced international investment bankers and will advise on important corporate finance and other strategic activities in the years ahead.”

Dr. Snyderman is chancellor emeritus at Duke University, James B. Duke professor of medicine, and director of the Center for Research on Personalized Health Care.  He served as chancellor for health affairs and dean of the Duke University School of Medicine from 1989 to 2004.  During this time, he oversaw the development of the Duke University Health System and served as its first president and chief executive officer. Dr. Snyderman has played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery.  Previously, Dr. Snyderman served as senior vice president for medical research and development at Genentech, Inc., the pioneering biomedical technology firm.  He has played a leadership role in important national organizations such as the Association of American Physicians, the National Academy of Medicine, and Association of American Medical Colleges. Dr. Snyderman earned a doctor of medicine degree from SUNY Downstate Medical Center.

Mr. Mtibelishvily is currently managing director and chairman of corporate and investment banking in Central and Eastern Europe, the Middle East and Africa for Citigroup, where he has served in various roles for nearly two decades. A specialist in corporate finance, capital markets, securities, and mergers and acquisitions, Mr. Mtibelishvily also has experience working with the multinational law firm Clifford Chance LLP. He earned a master of international legal studies degree from the Moscow State Institute of International Relations and a master of laws degree from the University of Virginia Law School.

Dr. Snyderman and Mr. Mtibelishvily will replace vacating Argos directors Philippe Van Holle, M.B.A., and Andrei Petrov, Ph.D.

“On behalf of the management team, board of directors and shareholders, I would like to thank Philippe and Andrei for their dedication and support over the last several years,” said Hubert Birner, Ph.D., chairman of the Argos board of directors. “They each have played an instrumental role in the growth and development of Argos.”

About the Arcelis® Technology Platform Arcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient’s own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma, and administered via intradermal injection as an individualized immunotherapy.

About Argos Therapeutics Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003 , is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).  In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis® -based product candidate, AGS-004 , for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

Forward Looking Statements Any statements in this press release about Argos’ future expectations, plans and prospects, including statements about the expected and potential future closings of the private placement, Argos’ financial prospects, anticipated use of proceeds, future operations and sufficiency of funds for future operations, clinical development of Argos’ product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," “may,” "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Argos' product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos’ Form 10-Q for the quarter ended September 30, 2016, which is on file with the SEC, and in other filings Argos makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Argos’ views as of the date hereof. Argos anticipates that subsequent events and developments will cause Argos’ views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos’ views as of any date subsequent to the date hereof.

Media contact: Adam Daley Berry & Company Public Relations 212-253-8881 adaley@berrypr.com Investor contact: John Menditto Argos Therapeutics, Inc. 919-908-0687 jmenditto@argostherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 38

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 106

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 122

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 101

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 161

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 142

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 79

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

Highlights and Expectations for AAR's Upcoming Earnings Call

Updated Category News Views 102

AAR's Upcoming Earnings Release AAR (NYSE:AIR) is set to unveil its quarterly earnings report soon. Investors keenly await this announcement, hoping for positive surprises both in earnings and guidance for the future. Analysts’ Earnings Expectations Analysts predict that AAR will post an earnings per share (EPS) of $1.03. This figure reflects the optimism surrounding...

Continue Reading
Tradeweb Markets Reports Significant Trading Volume Growth

Updated Category News Views 218

Tradeweb Markets Sees Record Trading Volume in January Tradeweb Markets Inc. (NASDAQ: TW), a premier global provider of electronic marketplaces for trading various financial instruments, reported a phenomenal total trading volume of $54.6 trillion for January 2025. This figure represents an average daily volume (ADV) of approximately $2.44 trillion, showcasing a robust...

Continue Reading
Cal Water Celebrates EPA Recognition for Water Efficiency Efforts

Updated Category News Views 73

California Water Service, trading under NYSE: CWT, scored a big win back in 2024 when it snagged the U. S. Environmental Protection Agency’s (EPA) WaterSense Excellence in Promoting WaterSense Labeled Products Award for the second consecutive year. This ain't just fluff; it reflects a serious commitment to pushing water-efficient solutions that resonate with their...

Continue Reading
Navigating Market Trends: Key Earnings Week Insights

Updated Category News Views 125

Market Trends Before Earnings As we enter a pivotal earnings week, investors are feeling the pressure as tech stocks have led the way downwards. This anticipated decline comes as many anticipate significant corporate earnings that could either uplift or hamper the current record-setting rally in the markets. Stock Performance and Investor Sentiment On this busy Monday...

Continue Reading
Revolutionizing Insurance Research: The Game-Changer ZORRO Discover

Updated Category News Views 145

Introduction to ZORRO Discover ZestyAI has unveiled a groundbreaking tool aimed at transforming the insurance industry: ZORRO Discover. This innovative generative AI agent is set to revolutionize the way insurers handle regulatory filings and competitive market analysis, potentially reshaping operational strategies across the board. Significance of ZORRO Discover...

Continue Reading